Navigation Links
PsiPort ™ Mass Directed Auto Purification Software from Shimadzu Biotech

ProductsPsiPort ™ Mass Directed Auto Purification Software from Shimadzu Biotech
Company Shimadzu Biotech
Item PsiPort ™ Mass Directed Auto Purification Software
Price 
Description Shimadzu Biotech presents PsiPort Mass Directed Auto Purification software, a web-based data review and data acquisition system designed for automated compound isolation and purification for the life science and pharmaceutical discovery programs. The system has been designed specifically to simplify high throughput mass directed auto purification for synthetic chemists using a simple, intuitive, graphical user interface operating within Internet Explorer. PsiPort is the Web-based solution for sample log-in and interactive data review (Microsoft Internet Explorer browser shows MS chromatogram, MS spectrum, UV chromatogram and associated fraction id) and features a fully distributed client-server architecture for data review either within a secure company intranet or over the Internet.

Key features

  • Chemists and biochemists do not need to be trained on mass spectrometry software.
  • Web-based solution for sample log-in and interactive data review (Microsoft Internet Explorer browser shows MS chromatogram, MS spectrum, UV chromatogram and associated fraction id).
  • Automates compound isolation and purification through a single web-based interface (enter target mass information through a wizard or use Microsoft Excel).
  • Fully distributed client-server architecture for data review either within a secure company intranet or over the Internet.
Software design
PsiPort Mass Directed Auto Purification software has been designed in a two tier approach to accelerating compound isolation and purification through a generic web based interface.

Access to PsiPort
Access to the PsiPort system is managed and controlled by the System Manager | Administrator to provide full system security. Access can be either local or remote using the integrated client-server support (Microsoft Internet Information Services).

Sample log-in and acquisition
Chemists may submit samples either using a spreadsheet from an external database (Microsoft Excel for example) or a wizard function for a limited number of samples. Each sample contains all the user defined acquisition information (for example target mass, formulae, MS and UV thresholds and a pre-assigned LC/MS method which also includes a specific customized report layout).

Info Shimadzu BiotechShimadzu Biotech
Japan/Asia
Shimadzu Corporation
1 Nishinokyo Kuwabaracho
Nakagyoku, Kyoto 604-8511
Japan
Phone: +81-75-823-1148
Fax: +81-75-823-1364
info@shimadzu-biotech.net

United States
Shimadzu Biotech USA
7102 Riverwood Drive
Columbia, Maryland 21046 USA
Phone: 800-477-1227/410-381-1227
info@shimadzu-biotech.net

England
Shimadzu Biotech
Wharfside
Trafford Wharf Road
Manchester
M17 1GP
England
Tel +44 161 888 4414
Fax +44 161 888 4402
MALDI
chris.sutton@kratos.co.uk
LCMS
nl@shimadzu.de

For contacts in other regions
please click here.

Customer Service: see above
Fax Number: see above
Web Site: http://www.shimadzu-biotech.net
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. Cleland’s REDUCTACRYL™ Reagent from Calbiochem
2. Transformance™ competent cell preparation service from Lucigen
3. EvoQuest ™ Custom Laboratory Services from Invitrogen
4. GST•Tag™ Antibody Plate from Novagen
5. pTriEx™-4 DNA from Novagen
6. ReBlot™ Plus Kit - Trial from CHEMICON
7. NanoMate ™ 100 with ESI Chip Technology from Advion Biosciences, Inc.
8. GrabIt™ Protein G Plus/Protein A Kit from Novagen
9. Cell invasion Fluorometric (green) Assay Kit, InnoCyte™ from Calbiochem
10. mirVana™ miRNA Bioarray Essentials Kit from Ambion
11. CaspaTag™ Pan-Caspase In Situ Assay Kit, Sulforhodamine from CHEMICON
Human Xg Affinity Purified Polyclonal Ab Keywords: Xg glycoprotein, hereditary hemorrhagic telangiectasia Protein Family: ...
nuclear RNA export factor 1, mRNA...
Mycoplasma tested...
Human PDGF, CF...
Biology Products:
(Date:10/16/2014)... constantly wages war on the human body. Battles ... stalemate. In pancreatic cancer, this stalemate—known as tumor ... aggressively malignant, a phenomena that is poorly understood. ... the laboratory of Salvatore Torquato, a Professor of ... conditions surrounding tumor dormancy and the switch to ...
(Date:10/16/2014)... researchers have challenged conventional thinking on how the bowel ... mechanism for how bowel cancer starts. , The researchers ... and regenerating the ,crypts, that are a feature of ... involved in bowel cancer development, a controversial finding as ... , Using 3D imaging technologies, Dr Chin Wee Tan ...
(Date:10/16/2014)... 16, 2014) – Post-menopausal women experienced improvements in ... levels or genital bleeding, after 12 weeks of ... fermented soy germ-based nutritional supplement previously shown to ... new peer-reviewed pilot study reported in a poster ... scientific meeting. , "These data documented improved ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2Cryptic clues drive new theory of bowel cancer development 2S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2
... By manipulating highly specific gene-regulating molecules called microRNAs, scientists at ... in singling out and repressing stem-like cells in mouse breast ... to cancer. If certain forms of breast cancer do ... believe to be the case, then it is critical to ...
... induce cells to form parallel tube-like structures that could one ... found that they can control the cells, development by growing ... the work was posted this month in an online issue ... day be transplanted into tissues such as the kidneys, liver, ...
... events that are critical to a healthy life, giving ... to think. But thats if the neurotransmitters are getting ... cells, neurons or other cells. Now a ... transcription factor that controls a neurotransmitter in the nematode ...
Cached Biology News:CSHL scientists identify and repress breast cancer stem cells in mouse tissue 2CSHL scientists identify and repress breast cancer stem cells in mouse tissue 3MIT works toward engineered blood vessels 2Overexcited neurons not good for cell health 2Overexcited neurons not good for cell health 3
(Date:10/22/2014)... 22, 2014   Synthetic Biologics, Inc. (NYSE ... for serious infections and diseases, announced today that the ... of Allowance for a composition of matter patent application ... program, SYN-004. This is Synthetic Biologics, first allowed ... and adds to the Company,s extensive C. difficile ...
(Date:10/22/2014)... and HONG KONG , Oct. ... disease therapeutics enterprise, announced today that rare disease expert ... as vice president, research. Dr. McKew brings more than ... leadership positions at the National Institutes of Health, Wyeth ... by Wyeth). Dr. McKew will lead aTyr,s efforts to expand ...
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
(Date:10/20/2014)... PureTech , a science and technology development ... today the closing of a $55 million growth ... a $120 Billion group of funds. The funding ... forward and to advance new healthcare related products ... really go for the big ideas that can ...
Breaking Biology Technology:Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6